MIACALCIN (calcitonin salmon) by Viatris is agonist. Approved for symptomatic paget's disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase, urinary hydroxyproline excretion, postmenopausal osteoporosis in women greater than 5 years postmenopause and 3 more indications. First approved in 1986.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
MIACALCIN (calcitonin salmon) is an injectable calcitonin agonist that acts on bone, renal, and gastrointestinal tissues to regulate calcium metabolism. It treats postmenopausal osteoporosis, Paget's disease of bone, and hypercalcemia by inhibiting osteoclast activity and promoting bone resorption reduction. Calcitonin salmon has greater potency per mg and longer duration of action compared to mammalian-origin calcitonins.
Product is approaching loss of exclusivity with minimal current market spend ($837K annually), indicating a small, specialized team focused on maintaining legacy indication revenue.
agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer…
Calcitonin
Worked on MIACALCIN at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
MIACALCIN offers limited career growth potential as a legacy product approaching loss of exclusivity with minimal linked job openings. Career opportunities are concentrated in operational roles (supply chain, compliance) or in defending existing market share rather than driving innovation or expansion.